Determination of henatinib in human plasma and urine by liquid chromatography–tandem mass spectrometry and its pharmacokinetic application

Abstract

Henatinib is a novel oral small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities in preclinical studies. In support of a clinical pharmacokinetic study, a simple, sensitive and rapid liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantification of henatinib in human plasma and urine. The sample preparation procedure involved a simple protein precipitation with methanol and the addition of midazolam as the internal standard. The chromatographic separation was achieved on an XBridge C18 column (50mm×2.1mm, 2.5μm) using a mixture of 5mM ammonium formate (pH 9.5)–acetonitrile–methanol (60:30:10, v/v/v) as the mobile phase. The MS/MS detection was performed in the positive ion multiple reaction monitoring (MRM) mode by monitoring the precursor→product ion transitions at m/z 469.1→382.2 for henatinib and m/z 326.2→291.3 for the internal standard. Assays were validated over the concentration range of 0.100–400ng/mL and 1.00–2500ng/mL for plasma and urine, respectively. The established method was highly sensitive with the lower limit of quantification (LLOQ) of 0.100ng/mL and 1.00ng/mL for plasma and urine, respectively. The intra- and inter-day precisions were <8.6% and <9.2% for plasma and urine, respectively. The mean assay accuracy was within ±6.8% of nominal values for both plasma and urine. The analytical runtime within 3.5min per sample made this method suitable for high-throughput determination. The validated method was successfully applied to a phase I dose escalation pharmacokinetic study in Chinese cancer patients.